A role for metabolomics in the antidoping toolbox?
antidoping
athletic performance
hormones
metabolomics
Journal
Drug testing and analysis
ISSN: 1942-7611
Titre abrégé: Drug Test Anal
Pays: England
ID NLM: 101483449
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
18
09
2019
revised:
30
01
2020
accepted:
05
03
2020
pubmed:
8
3
2020
medline:
1
4
2021
entrez:
8
3
2020
Statut:
ppublish
Résumé
Evidence of the continuous rise of novel doping agents and novel doping strategies calls for the development of more accurate multi-target screening methods. Direct multi-target screening approaches are restricted to the targeted substances and their turnover. The development of effective "indirect" screening methods requires a priori a deep understanding of the metabolism of the substance. The biological passport has been demonstrated to be very effective, but it is limited to about 20 indirect parameters. The standard antidoping analytical methods are hence targeted and do not aim directly to identify unknown substances. Also, the detection of doping agents is limited by the excretion of the substance. This study considers metabolomics for the screening of performance enhancing hormone abuse by athletes, based on the following pieces of evidence: (1) hormones have a strong influence on human metabolism, changing several parameters in many tissues, organs, and bio-fluids; (2) metabolomics has been demonstrated to be a very accurate tool to depict the metabolic status of several organisms, tissues, and for several human diseases, including hormone deficiencies; (3) metabolomics has been demonstrated to be able to distinguish hormone-treated animals from controls in many species, without the need for a priori knowledge of the metabolism for the specific substance. The literature shows that metabolomics could be an appropriate tool to detect hormone abuse, keeping in mind the strength and the limitation of such an approach.
Substances chimiques
Hormones
0
Performance-Enhancing Substances
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
677-690Informations de copyright
© 2020 John Wiley & Sons, Ltd.
Références
WADA. https://www.Wada-Ama.Org/Sites/Default/Files/Wada_2020_english_prohibited_list_0.Pdf, 2020.
Fernandez MMF, Hosey RG. Performance-enhancing drugs snare nonathletes, too. J Fam Pract. 2009;58(1):16-23.
Kabiri S, Cochran JK, Stewart BJ, Sharepour M, Rahmati MM, Shadmanfaat SM. Doping among professional athletes in Iran: a test of Akers's social learning theory. Int J Offender Ther Comp Criminol Criminol. 2016;11:1-26.
Frenger M, Pitsch W, Emrich E. Sport-induced substance use - an empirical study to the extent within a German sports association. PLoS One. 2016;10:1-17.
Dietz P, Ulrich R, Dalaker R, et al. Associations between physical and cognitive doping - a cross-sectional study in 2997 triathletes. PLoS One. 2013;8:1-10.
Strulik H. Riding high: success in sports and the rise of doping cultures. Scand J Econ. 2012;14:539-574.
Elbe A-M, Pitsch W. Doping prevalence among Danish elite athletes. Perform Enhanc Heal. 2018;6:28-32.
Pitsch W, Emrich E, Klein M. Doping in elite sports in Germany: results of a www survey. Eur J Sport Soc. 2007;4:89-102.
Ulrich R, Pope HG, Cléret L, et al. Doping in two elite athletics competitions assessed by randomized-response surveys. Sport Med. 2018;48:211-219.
Pielke R. Assessing doping prevalence is possible. So what are we waiting for? Sport. Med. 2018;48:207-209.
Backhouse S, Whitaker L, Patterson L, Erickson K, McKenna J. Social psychology of doping in sport: a mixed-studies narrative synthesis. Institute for Sport, Physical Activity and Leisure; 2015.
Pound RW, Ayotte C, Parkinson A, Pengilly A, Ryan A. Lack of effectiveness of testing programs report to Wada executive committee. 2012;1-9.
Gould D. Gene doping: gene delivery for olympic victory. Br J Clin Pharmacol. 2013;76:292-298.
Reardon C, Creado S. Drug abuse in athletes. Subst Abuse Rehabil. 2014;5:95-105.
Liposek S, Zenic N, Saavedra JM, et al. Examination of factors explaining coaching strategy and training methodology as correlates of potential doping behavior in high-level swimming. J Sport Sci Med. 2018;17:82-91.
Codella R, Glad B, Luzi L, La Torre A. An Italian campaign to promote anti-doping culture in high-school students. Front Physiol. 2019;10:1-5.
Goldman B, Bush P, Klatz R. Death in the Locker Room: Steroids and Sports. NCBI bookshelf; Icarus; 1983.
Connor J, Woolf J, Mazanov J. Would they dope? Revisiting the Goldman dilemma. Br J Sports Med. 2013;47(11):697-700.
Woolf J, Mazanov J, Connor J. The Goldman dilemma is dead: what elite athletes really think about doping, winning, and death. Int J Sport Policy. 2017;9:453-467.
González JM, Johnson FR, Fedoruk M, Posner J, Bowers L. Trading health risks for glory: a reformulation of the Goldman dilemma. Sport Med. 2018;48:1963-1969.
Mazanov J. What would Kim do: a choice study of projected athlete doping considerations. J Sport Manag. 2012;26:322-334.
Overbye M. Deterrence by risk of detection? An inquiry into how elite athletes perceive the deterrent effect of the doping testing regime in their sport. Drugs Educ Prev Policy ISSN. 2016;1-14.
Westmattelmann D, Dreiskämper D, Strauß B, Schewe G, Plass J. Perception of the current anti-doping regime - a quantitative study among German top-level cyclists and track and field athletes. Front Physiol. 2018;9:1-14.
WADA. “https://www.wada-ama.org/sites/default/files/resources/files/isl_nov2019.pdf,” 2019.
WADA. “https://www.wada-ama.org/sites/default/files/resources/files/2018_testing_figures_report.pdf,” 2018.
Elbe A-M, Pitschb W. Doping prevalence among Danish elite athletes. Perform. Enhanc. Heal. 2018;6:28-32.
Mavromati D. Indirect detection methods for doping from a legal perspective: the case of the athlete biological passport. Int J Sport Policy. 2014;6:241-258.
Delanghe JR, Bollen M, Beullens M. Testing for recombinant erythropoietin. Am J Hematol. 2007;82:916-919.
Ashenden M, Varlet-Marie E, Lasne F, Audran M. The effects of microdose recombinant human erythropoietin regimens in athletes. Haematologica. 2006;91(8):1143-1144.
Ashenden M, Gough CE, Garnham A, Gore CJ, Sharpe K. Current markers of the athlete blood passport do not flag microdose EPO doping. Eur J Appl Physiol. 2011;111:2307-2314.
Wang G, Karanikolou A, Verdouka I, Friedmann T, Pitsiladis Y. Next generation “omics” approaches in the “fight” against blood doping. Med Sport Sci. 2017;62:119-128.
Brzeziańska E, Domańska D, Jegier A. Gene doping in sport - perspectives and risks. Biol Sport. 2014;31:251-259.
Duchaine D. Underground steroid handbook II. Venice: HLR Tech. Books. 1989.
Diamanti-Kandarakis E, Tsilakis D, Lazarides S, Kandarakis H, Bergele A. Hormones in sports: growth hormone abuse. Hormones. 2004;3(1):37-45.
Reichel C. OMICS-strategies and methods in the fight against doping. Forensic Sci Int. 2011;213(1-3):20-34.
Kay RG, Creaser CS. Application of mass spectrometry-based proteomics techniques for the detection of protein doping in sports. Expert Rev Proteomics. 2010;7:185-188.
King CC, Bouic K, Friedmann T. A fractionation method to identify quantitative changes in protein expression mediated by IGF-1 on the proteome of murine C2C12 myoblasts. Proteome Sci. 2009;7:1-18.
Duran-Ortiz S, Brittain AL, Kopchick JJ. The impact of growth hormone on proteomic profiles: a review of mouse and adult human studies. Clin Proteomics. 2017;14:1-22.
Zhan X, Desiderio DM. The use of variations in proteomes to predict, prevent, and personalize treatment for clinically nonfunctional pituitary adenomas. EPMA J. 2010;1(3):439-459.
Sock Hwee T, Lee A, Pascovici D, et al. Plasma biomarker proteins for detection of human growth hormone administration in athletes. Sci Rep. 2017;7:1-12.
Ramautar R, Berger R, van der Greef J, Hankemeier T. Human metabolomics: strategies to understand biology. Curr Opin Chem Biol. 2013;17(5):841-846.
Hoybye C, Wahlstrom E, Tollet-Egnell P, Norstedt G. Metabolomics: a tool for the diagnosis of GH deficiency and for monitoring GH replacement? Endocr Connect. 2014;3(4):200-206.
Wu Q, Lai X-L, Zhao H-X, et al. A metabolomics approach for predicting the response to intravenous iron therapy in peritoneal dialysis patients with anemia. RSC Adv. 2017;7:1915-1922.
Jeanneret F, Tonoli D, Rossier MF, Saugy M, Boccard J, Rudaz S. Evaluation of steroidomics by liquid chromatography hyphenated to mass spectrometry as a powerful analytical strategy for measuring human steroid perturbations. J Chromatogr A J. 2016;1430:97-112.
Ponzetto F, Boccard J, Nicoli R, Kuuranne T, Saugy M, Rudaz S. Steroidomics for highlighting novel serum biomarkers of testosterone doping. Bioanalysis. 2019;11:1169-1185.
Ponzetto F, Mehl F, Boccard J, et al. Longitudinal monitoring of endogenous steroids in human serum by UHPLC-MS/MS as a tool to detect testosterone abuse in sports. Anal Bioanal Chem. 2016;408(3):705-719.
Badoud F, Boccard J, Schweizer C, Pralong F, Saugy M, Baume N. Profiling of steroid metabolites after transdermal and oral administration of testosterone by ultra-high pressure liquid chromatography coupled to quadrupole time-of-flight mass spectrometry. J Steroid Biochem Mol Biol. 2013;138:222-235.
Van Renterghem P, Van Eenoo P, Sottas PE, Saugy M, Delbeke F. Subject-based steroid profiling and the determination of novel biomarkers for DHT and DHEA misuse in sports. Drug Test Anal. 2010;2:582-588.
Van Renterghem P, Van Eenoo P, Sottas PE, Saugy M, Delbeke F. A pilot study on subject-based comprehensive steroid profiling: novel biomarkers to detect testosterone misuse in sports. Clin Endocrinol (Oxf). 2011;75:134-140.
Piper T, Schänzer W, Thevis M. Genotype-dependent metabolism of exogenous testosterone - new biomarkers result in prolonged detectability. Drug Test Anal. 2016;8(11-12):1163-1173.
Fabregat A, Pozo OJ, Marcos J, Segura J, Ventura R. Alternative markers for the long-term detection of oral testosterone misuse. Steroids. 2011;76(12):1367-1376.
Li X, Zhang P. Advances in anti-doping analytical approaches: challenges and solutions. Curr Pharm Anal. 2017;14:167-174.
Botrè F. Mass spectrometry and illicit drug testing: analytical challenges of the anti-doping laboratories. Expert Rev Proteomics. 2008;5(4):535-539.
Geyer H, Schänzer W, Thevis M. Anabolic agents: recent strategies for their detection and protection from inadvertent doping. Br J Sports Med. 2014;48(10):820-826.
Handelsman DJ. Performance Enhancing Hormone Doping in Sport. NCBI Bookshelf a Serv Natl Libr Med Natl Institutes Heal. 2000;1-29.
Barbalho MD, Barreiros FP. The use of anabolic- androgenic steroids in sports. Int J Sport Sci. 2015;5:171-179.
WADA. “https://www.wada-ama.org/sites/default/files/resources/files/wada_anti-doping_code_2019_english_final_revised_v1_linked.pdf,” 2019.
Musenga A, Cowan DA. Use of ultra-high pressure liquid chromatography coupled to high resolution mass spectrometry for fast screening in high throughput doping control. J Chromatogr A. 2013;1288:82-95.
Pereira HMG, Sardela VF, Padilha MC, et al. Doping control analysis at the Rio 2016 Olympic and Paralympic games. Drug Test Anal. 2017;9:1658-1672.
Pereira H, Padilha M, Bento R, Cunha T, Lascas N, Aquino Neto F. Analytical and logistical improvements in doping-control analysis at the 2007 pan-American games. Trends Anal Chem. 2008;27:648-656.
WADA. TD2018EAAS. 2018.
Powrie JK, Bassett EE, Rosen T, et al. Detection of growth hormone abuse in sport. Growth Horm IGF Res. 2007;17(3):220-226.
WADA. Guidelines HGH isoform differential immunoassays. 2014.
Thevis M, Thomas A, Delahaut P, Bosseloir A, Schänzer W. Doping control analysis of intact rapid-acting insulin analogues in human ussrine by liquid chromatography-tandem mass spectrometry. Anal Chem. 2006;78:1897-1903.
Judák P, Van Eenoo P, Deventer K. Utilizing ELISA-plate based immunopurification and liquid chromatography-tandem mass spectrometry for the urinary detection of short- and long acting human insulin analogues. J Pharm Biomed Anal. 2018;153:76-81.
Parisotto R, Wu M, Ashenden MJ, et al. Detection of recombinant human erythropoietin abuse in athletes utilizing markers of altered erythropoiesis. Haematologica. 2001;86(2):128-137.
Gore CJ, Parisotto R, Ashenden MJ, et al. Second-generation blood tests to detect erythropoietin abuse by athletes. Haematologica. 2003;88:1053-1062.
Sottas PE, Saugy M, Saudan C. Endogenous steroid profiling in the athlete biological passport. Endocrinol Metab Clin North Am. 2010;39:59-73.
Lasne F, Martin L, Crepin N, De Ceaurriz J. Detection of isoelectric profiles of erythropoietin in urine: differentiation of natural and administered recombinant hormones. Anal Biochem. 2002;311:119-126.
Reihlen P, Blobel M, Kempkes R, et al. Optimizing SAR-PAGE. Drug Test Anal. 2015;7(11-12):1014-1016.
Lehtihet M, Bhuiyan H, Dalby A, Ericsson M, Ekström L. Longitudinally monitoring of P-III-NP, IGF-I, and GH-2000 score increases the probability of detecting two weeks’ administration of low-dose recombinant growth hormone compared to GH-2000 decision limit and GH isoform test and micro RNA markers. Drug Test Anal. 2018;11:411-421.
Martin L, Ashenden M, Bejder J, et al. New insights for identification of doping with recombinant human erythropoietin micro- doses after high hydration. Drug Test Anal. 2016;8(11-12):1119-1130. https://doi.org/10.1002/dta.2004
Møller V. The road to hell is paved with good intentions - a critical evaluation of WADA's anti-doping campaign. Perform Enhanc Heal. 2016;4:111-115.
Gleaves J, Christiansen AV. Athletes’ perspectives on WADA and the code: a review and analysis. Int J Sport Policy Polit. 2019;10:1-13.
Erotokritou-Mulligan I, Guha N, Stow M, et al. The development of decision limits for the implementation of the GH-2000 detection methodology using current commercial insulin-like growth factor-I and amino-terminal pro-peptide of type III collagen assays. Growth Horm IGF Res. 2012;22(2):53-58.
Saugy M, Lundby C, Robinson N. Monitoring of biological markers indicative of doping: the athlete biological passport. Br J Sports Med. 2014;48:827-832.
Ashenden M. A strategy to deter blood doping in sport. Haematologica. 2002;87(3):225-232.
Jelkmann W, Lundby C. Blood doping and its detection. Blood. 2011;118:2395-2404.
Mareck U, Geyer H, Opfermann G, Thevis M, Schanzer W. Factors influencing the steroid profile in doping control analysis. J Mass Spectrom. 2008;43(7):877-891.
Boyard-Kieken F, Dervilly-Pinel G, Garcia P, et al. Comparison of different liquid chromatography stationary phases in LC-HRMS metabolomics for the detection of recombinant growth hormone doping control. J Sep Sci. 2011;34:3493-3501.
Iljukov S, Bermon S, Schumacher YO. Application of the athlete's performance passport for doping control: a case report. Front Physiol. 2018;9:1-4.
Sottas PE, Vernec A. Current implementation and future of the athlete biological passport. Bioanalysis. 2012;4(13):1645-1652.
Banfi G. Limits and pitfalls of athletes biological passport. Clin Chem Lab Med. 2011;49(9):1417-1421.
Lippi G, Plebani M, Sanchis-Gomar F, Banfi G. Current limitations and future perspectives of the athlete blood passport. Eur J Appl Physiol. 2012;112(10):3693-3694.
Hopker J, Schumacher YO, Fedoruk M, et al. Athlete performance monitoring in anti-doping. Front Physiol. 2018;9:1-4.
Oliver S, Böttcher C, Neumann S, et al. Systematic functional analysis of the yeast genome. Trends Biotechnol. 1998;16:373-378.
Kell DB, Oliver SG. The metabolome 18 years on: a concept comes of age. Metabolomics. 2016;12:1-8.
Umberger EJ. Products marketed to PROMOTE growth in food-producing animals: steroid and hormone products*. Toxicology. 1975;3(1):3-21.
Kopchick JJ, Cioffi JA. Exogenous and endogenous effects of growth hormone in animals. Livest Prod Sci. 1991;27:61-75.
Wood AA, Foo TK, Ahmad M, Wood SA. Clenbuterol: effects and usage in livestock and show animals. NCBI bookshelf. 2010.
Stephany RW. Hormones in meat: different approaches in the EU and in the USA. APMIS Suppl. 2001;2001:S357-S363.
Pinel G, André F, Le Bizec B. Discrimination of recombinant and pituitary-derived bovine and porcine growth hormones by peptide mass mapping. J Agric Food Chem. 2004;52(3):407-414.
Bailly-Chouriberry L, Pinel G, Garcia P, Popot MA, Le Bizec B, Bonnaire Y. Identification of recombinant equine growth hormone in horse plasma by LC MS/MS: a confirmatory analysis in doping control. Anal Chem. 2008;80(21):8340-8347.
Rochereau-Roulet S, Gaudin I, Chéreau S, et al. Development and validation of an enzyme-linked immunosorbent assay for the detection of circulating antibodies raised against growth hormone as a consequence of rbST treatment in cows. Anal Chim Acta. 2011;700(1-2):189-193.
Rochereau-Roulet S, Gicquiau A, Morvan ML, Blanc G, Dervilly-Pinel G, Le Bizec B. Recombinant bovine growth hormone identification and the kinetic of elimination in rainbow trout treated by LC-MS/MS. Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2013;30(6):1020-1026.
Ellis DI, Muhamadali H, Allen DP, Elliott CT, Goodacre R. A flavour of omics approaches for the detection of food fraud. Curr Opin Food Sci. 2016;10:7-15.
Witkamp RF. Genomics and systems biology - how relevant are the developments to veterinary pharmacology, toxicology and therapeutics? J Vet Pharmacol Ther. 2005;28:235-245.
Mooney MH, Elliott CT, Le Bizec B. Combining biomarker screening and mass-spectrometric analysis to detect hormone abuse in cattle. Trends Anal Chem. 2009;28:665-675.
Nebbia C, Urbani A, Carletti M, et al. Novel strategies for tracing the exposure of meat cattle to illegal growth-promoters. Vet J. 2011;189:34-42.
Dervilly-Pinel G, Courant F, Chéreau S, et al. Metabolomics in food analysis: application to the control of forbidden substances. Drug Test Anal. 2012;4:59-69.
Fragkaki AG, Kioukia-Fougia N, Kiousi P, Kioussi M, Tsivou M. Challenges in detecting substances for equine anti-doping. Drug Test Anal. 2017;9(9):1291-1303.
Courant F, Pinel G, Bichon E, Monteau F, Antignac JP, Le Bizec B. Development of a metabolomic approach based on liquid chromatography-high resolution mass spectrometry to screen for clenbuterol abuse in calves. Analyst. 2009;134:1637-1646.
Van Meulebroek L, Wauters J, Pomian B, et al. Discovery of urinary biomarkers to discriminate between exogenous and semi-endogenous thiouracil in cattle: a parallel-like randomized design. PLoS One. 2018;13:1-22.
Peng T, Royer AL, Guitton Y, Le Bizec B, Dervilly-Pinel G. Serum-based metabolomics characterization of pigs treated with ractopamine. Metabolomics. 2017;13:1-15.
Dervilly-Pinel G, Royer A-L, Bozetta E, et al. When LC-HRMS metabolomics gets ISO17025 accredited and ready for official controls - application to the screening of forbidden compounds in livestock. Food Addit Contam Part a. 2018;35:1948-1958.
Dervilly-Pinel G, Chereau S, Cesbron N, Monteau F, Le Bizec B. LC-HRMS based metabolomics screening model to detect various ß-agonists treatments in bovines. Metabolomics. 2015;11:403-411.
Peng ML, Han J, Li LL, Ma HT. Metabolomics reveals the mechanism of (−)-hydroxycitric acid promotion of protein synthesis and inhibition of fatty acid synthesis in broiler chickens. Animal. 2018;12(4):774-783.
Regal P, Anizan S, Antignac JP, Le Bizec B, Cepeda A, Fente C. Metabolomic approach based on liquid chromatography coupled to high resolution mass spectrometry to screen for the illegal use of estradiol and progesterone in cattle. Anal Chim Acta. 2011;700(1-2):16-25.
Jacob CC, Dervilly-Pinel G, Biancotto G, Monteau F, Le Bizec B. Global urine fingerprinting by LC-ESI(+)-HRMS for better characterization of metabolic pathway disruption upon anabolic practices in bovine. Metabolomics. 2014;11:184-197.
Dervilly-Pinel G, Weigel S, Lommen A, et al. Assessment of two complementary liquid chromatography coupled to high resolution mass spectrometry metabolomics strategies for the screening of anabolic steroid treatment in calves. Anal Chim Acta. 2011;700(1-2):144-154.
Kouassi Nzoughet J, Dervilly-Pinel G, Chéreau S, et al. First insights into serum metabolomics of trenbolone/estradiol implanted bovines; screening model to predict hormone-treated and control animals' status. Metabolomics. 2015;11:1184-1196.
Kouassi Nzoughet J, Gallart-Ayala H, Biancotto G, Hennig K, Dervilly-Pinel G, Le Bizec B. Hydrophilic interaction (HILIC) and reverse phase liquid chromatography (RPLC)-high resolution MS for characterizing lipids profile disruption in serum of anabolic implanted bovines. Metabolomics. 2015;11:1884-1895.
Graham SF, Ruiz-Aracama A, Lommen A, et al. Use of NMR metabolomic plasma profiling methodologies to identify illicit growth-promoting administrations. Anal Bioanal Chem. 2012;403:573-582.
Kinkead RA, Elliott CT, Cannizzo FT, Biolatti B, Gadaj A, Mooney MH. Plasma metabolomic profiling based detection of drug specific responses to different bovine growth promoting regimes. Food Control. 2018;86:146-158.
Kaabia Z, Dervilly-Pinel G, Popot MA, et al. Monitoring the endogenous steroid profile disruption in urine and blood upon nandrolone administration: an efficient and innovative strategy to screen for nandrolone abuse in entire male horses. Drug Test Anal. 2014;6:376-388.
Stojiljkovic N, Bubanj S, Djordjevic M, et al. Urine fingerprints of Stanozolol treated horses by liquid chromatography high resolution mass spectrometry. J Sports Med Doping Stud. 2017;07:1-9.
Kieken F, Pinel G, Antignac JP, et al. Development of a metabonomic approach based on LC-ESI-HRMS measurements for profiling of metabolic changes induced by recombinant equine growth hormone in horse urine. Anal Bioanal Chem. 2009;394(8):2119-2128.
Kieken F, Pinel G, Antignac JP, et al. Generation and processing of urinary and plasmatic metabolomic fingerprints to reveal an illegal administration of recombinant equine growth hormone from LC-HRMS measurements. Metabolomics. 2011;7:84-93.
Joré C, Loup B, Garcia P, et al. Human urine metabolic fingerprints by LC-HRMS for ESA doping control. 2017;1.
Marchand J, Martineau E, Guitton Y, Le Bizec B, Dervilly-Pinel G, Giraudeau P. A multidimensional 1 H NMR lipidomics workflow to address chemical food safety issues. Metabolomics. 2018;14:1-11.
Bligh E, Dyer W. Canadian journal of biochemistry and physiology. J Biochem Physiol. 1959;37:911-917.
Bylesjo M, Rantalainen M, Cloarec O, Nicholson JK, Holmes E, Trygg J. OPLS discriminant analysis: combining the strengths of PLS-DA and SIMCA classification. J Chemometr. 2007;398-405.
Dervilly-Pinel G, Prévost S, Monteau F, Le Bizec B. Analytical strategies to detect use of recombinant bovine somatotropin in food-producing animals. Trends Anal Chem. 2014;53:1-10.
Walder A, Baumann P. Increased creatinine kinase and rhabdomyolysis in anorexia nervosa. Int J Eat Disord. 2008;41:766-767.
Boccard J, Badoud F, Grata E, et al. A steroidomic approach for biomarkers discovery in doping control. Forensic Sci Int J. 2011;213:85-94.
Palermo A, Botrè F, de la Torre X, Zamboni N. Non-targeted LC-MS based metabolomics analysis of the urinary steroidal profile. Anal Chim Acta. 2017;964:112-122.
Raro M, Ibanez M, Gil R, et al. Untargeted metabolomics in doping control: detection of new markers of testosterone misuse by ultrahigh performance liquid chromatography coupled to high-resolution mass spectrometry. Anal Chem. 2015;87:8373-8380.
Kiss A, Jacquet A-L, Paisse O, et al. Urinary signature of anabolic steroids and glucocorticoids in humans by LC-MS. Talanta. 2011;83(5):1769-1773.
Boccard J, Badoud F, Nicolas J, et al. Untargeted profiling of urinary steroid metabolites after testosterone ingestion: opening new perspectives for antidoping testing. Bioanalysis. 2014;6:2523-2536.
Kiss A, Lucio M, Fildier A, Buisson C, Schmitt-Kopplin P, Cren-Olivé C. Doping control using high and ultra-high resolution mass spectrometry based non-targeted metabolomics - a case study of salbutamol and budesonide abuse. PLoS One. 2013;8:1-13.
Al-Khelaifi F, Diboun I, Donati F, et al. Metabolomics profiling of xenobiotics in elite athletes: relevance to supplement consumption. J Int Soc Sports Nutr. 2018;15:1-10.
Rodríguez-Morató J, Pozo ÓJ, Marcos J. Targeting human urinary metabolome by LC-MS/MS: a review. Bioanalysis. 2018;10(7):489-516.
Wang G, Durussel J, Shurlock J, et al. Validation of whole-blood transcriptome signature during microdose recombinant human erythropoietin (rHuEpo) administration. BMC Genomics. 2017;18:67-80.
Al-Khelaifi F, Diboun I, Donati F, et al. A pilot study comparing the metabolic profiles of elite-level athletes from different sporting disciplines. Sport Med - Open. 2018;4:1-15.
Robinson N, Sottas PE, Schumacher YO. The athlete biological passport: how to personalize anti-doping testing across an athlete's career? Med Sport Sci. 2017;62:107-118.
Lawler NG, Broadhurst DI, Thompson KG, et al. Characterizing the plasma metabolome during 14 days of live-high, train-low simulated altitude: a metabolomic approach. Exp Physiol. 2019;104(1):81-92.
Al-Khelaifi F, Yousri NA. Metabolic profiling of elite athletes with different cardiovascular demand. Scand J Med Sci Sport. 2019;29:933-943.
Nicholson JK, Connelly J, Lindon JC, Holmes E. Metabonomics: a platform for studying drug toxicity and gene function. Nat Rev Drug Discov. 2002;1:3-11.
Wang Y, Caldwell R, Cowan DA, Legido-Quigley C. LC-MS-based metabolomics discovers purine endogenous associations with low-dose salbutamol in urine collected for antidoping tests. Anal Chem. 2016;88:2243-2249.
Salamin O, Kuuranne T, Saugy M, Leuenberger N. Erythropoietin as a performance-enhancing drug: its mechanistic basis, detection, and potential adverse effects. Mol Cell Endocrinol. 2017;1-13.
Bhasin S, Woodhouse L, Casaburi R, et al. Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab. 2001;281:1172-1181.
Albertsson-Wikland K, Aronson AS, Gustafsson J, et al. Dose-dependent effect of growth hormone on final height in children with short stature without growth hormone deficiency. J Clin Endocrinol Metab. 2008;93:4342-4350.
Shackleton CHL. Role of a disordered steroid metabolome in the elucidation of sterol and steroid biosynthesis. Lipids. 2012;47(1):1-12.
Kotłowska A, Puzyn T, Sworczak K, Stepnowski P, Szefer P. Metabolomic biomarkers in urine of Cushing's syndrome patients. Int J Mol Sci. 2017;18:1-15.
Abd Rahman S, Schirra HJ, Lichanska AM, Huynh T, Leong GM. Urine metabonomic profiling of a female adolescent with PIT-1 mutation before and during growth hormone therapy: insights into the metabolic effects of growth hormone. Growth Horm IGF Res. 2013;23(1-2):29-36.
Koriem KMM. Protective effect of natural products and hormones in colon cancer using metabolome: a physiological overview. Asian Pac J Trop Biomed. 2017;7:957-966.
Estrada M, Liberona JL, Miranda M, Jaimovich E. Aldosterone- and testosterone-mediated intracellular calcium response in skeletal muscle cell cultures. Am J Physiol - Endocrinol Metab. 2000;279:132-139.
Achar S, Rostamian A, Narayan SM. Cardiac and metabolic effects of anabolic-androgenic steroid abuse on lipids, blood pressure, left ventricular dimensions, and rhythm. Am J Cardiol. 2010;106(6):893-901.
Abdulla H, Smith K, Atherton PJ, Idris I. Role of insulin in the regulation of human skeletal muscle protein synthesis and breakdown: a systematic review and meta-analysis. Diabetologia. 2016;59:44-55.
Vijayakumar A, Yakar S, LeRoith D. The intricate role of growth hormone in metabolism. Front Endocrinol (Lausanne). 2011;2:1-11.
Lanes R, Soros A, Gunczler P, et al. Growth hormone deficiency, low levels of adiponectin, and unfavorable plasma lipids and lipoproteins. J Pediatr. 2006;149(3):324-329.
Musumeci G, Trovato F, Avola R, Imbesi R, Castrogiovanni P. Serotonin/growth hormone/insulin-like growth factors axis on pre- and post-natal development: a contemporary review. OA Anat. 2013;2:1-7.
Thimmarayappa J, Sun J, Schultz LE, et al. Inhibition of growth hormone receptor gene expression by saturated fatty acids: role of Kru¨ ppel-like zinc finger factor, ZBP-89. Mol Endocrinol. 2006;20(11):2747-2760.
Wang L, Di L, Noguchi CT. Erythropoietin, a novel versatile player regulating energy metabolism beyond the erythroid system. Int J Biol Sci. 2014;10(8):921-939.
Ponce L, Navarro JC, Ahmed O, Robertson CS. Erythropoietin neuroprotection with traumatic brain injury. Pathophysiology. 2013;20(1):31-38.
Dimitrijevic ZM, Cvetkovic TP, Djordjevic VM, et al. How the duration period of erythropoietin treatment influences the oxidative status of hemodialysis patients. Int J Med Sci. 2012;9:808-815.
Ayala A, Muñoz MF, Argüelles S. Lipid peroxidation: production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal. Oxid Med Cell Longev. 2014;2014:1-31.
Fogarty MC, Hughes CM, Burke G, et al. Exercise-induced lipid peroxidation: implications for deoxyribonucleic acid damage and systemic free radical generation. Environ Mol Mutagen. 2011;52:35-42.
Alka B, Kapendra S. Hair analysis for the detection of misuse of drugs in sports: a perspective. Austin J Anal Pharm Chem. 2016;3:1-3.
Beck O. Exhaled breath for drugs of abuse testing - evaluation in criminal justice settings. Sci Justice. 2014;54:57-60.
Beck O, Sandqvist S, Böttcher M, Eriksen P, Franck J, Palmskog G. Study on the sampling of methadone from exhaled breath. J Anal Toxicol. 2011;35(5):257-263.